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We used Cox regression analyses to assess mortality outcomes in a combined cohort of 7675 women who received diethylstilbestrol
(DES) through clinical trial participation or prenatal care. In the combined cohort, the RR for DES in relation to all-cause mortality was
1.06 (95% CI¼0.98–1.16), and 1.11 (95% CI¼1.02–1.21) after adjusting for covariates and omitting breast cancer deaths. The RR
was 1.07 (95% CI¼0.94–1.23) for overall cancer mortality, and remained similar after adjusting for covariates and omitting breast
cancer deaths. The RR was 1.27 (95% CI¼0.96–1.69) for DES and breast cancer, and 1.38 (95% CI¼1.03–1.85) after covariate
adjustment. The RR was 1.82 in trial participants and 1.12 in the prenatal care cohort, but the DES–cohort interaction was not
significant (P¼0.15). Diethylstilbestrol did not increase mortality from gynaecologic cancers. In summary, diethylstilbestrol was
associated with a slight but significant increase in all-cause mortality, but was not significantly associated with overall cancer or
gynaecological cancer mortality. The association with breast cancer mortality was more evident in trial participants, who received high
DES doses.
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Starting in about 1940, diethylstilbestrol (DES), a powerful
nonsteroidal oestrogen, was used to prevent pregnancy loss and
complications. Although clinical trials conducted in the 1950s
showed DES was not effective (Dieckmann et al, 1953; Swyer and
Law, 1954), use continued for another two decades. Diethylstilbes-
trol was withdrawn from use during pregnancy in the early 1970s,
after it was shown that in utero exposure was strongly associated
with the risk of vaginal adenocarcinoma (Herbst et al, 1971). Until
that time, as many as 2 million women in the US (Noller and Fish,
1974), and 4 million women worldwide (Newbold, 1993) were
given DES during pregnancy.
Most studies, but not all (Vessey et al, 1983), have suggested a
positive association between DES taken during pregnancy and
breast cancer incidence (Bibbo et al, 1978; Clark and Portier, 1979;
Beral and Colwell, 1980; Greenberg et al, 1984; Hadjimichael et al,
1984; Colton et al, 1993; Titus-Ernstoff et al, 2001), although the
latter four studies produced findings compatible with chance. Of
the studies assessing DES in relation to breast cancer mortality,
one observed a significant association (Calle et al, 1996); four
produced suggestive findings that were not of statistical signifi-
cance (Bibbo et al, 1978; Clark and Portier, 1979; Hadjimichael
et al, 1984; Colton et al, 1993); and another found no association
(Greenberg et al, 1984). To date, only one study formally assessed
all-cause or disease-specific mortality outcomes, and found little
evidence of an association with DES (Greenberg et al, 1984). In the
present paper, we present findings based on the largest study to
date of mortality outcomes in women with documented DES
exposure.
MATERIALS AND METHODS
We assessed exposure to DES during pregnancy in relation to
cause-specific and total mortality, with a particular interest in
gynaecological cancers, and those known to be influenced by
exposure to exogenous oestrogen. The analyses were based on a
combined cohort, the design and methods of which have been
described previously (Titus-Ernstoff et al, 2001).
The combined cohort consists of DES-exposed and unexposed
women from two previous follow-up studies, the Women’s Health
Study (WHS) and the Dieckmann Study, both of which assessed
the long-term health consequences of DES exposure during
pregnancy. The WHS enrolled DES-exposed and unexposed
women who were ascertained through a retrospective review of
obstetrics records for the period 1940–1960 at the Mayo Clinic in
Rochester, MN; Mary Hitchcock Memorial Hospital in Hanover,
NH; a pregnancy clinic at the Boston Lying-In Hospital, in Boston,
MA; and a private obstetrics practice in Portland, ME (Greenberg
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Diethylstilbestrol-exposed women were those whose records
indicated that DES (or, rarely, another nonsteroidal oestrogen)
had been prescribed during at least one pregnancy resulting in a
live birth. The date of the first DES-exposed live birth was the
study entry date; unexposed women were matched within 72
years to the DES-exposed women’s birth dates, and were assigned
the same date of study entry as the exposed woman to whom they
were matched. Active follow-up of the WHS cohort was
implemented in the early 1980s and continued intermittently
through 1989.
The second cohort consists of women who participated in the
Dieckmann Study, a placebo-controlled clinical trial of the effects
of DES on pregnancy losses. The trial was conducted in the early
1950s at the University of Chicago, and enrolled women who were
6–20 weeks pregnant. The cumulative dose of DES tested was 11–
12g. For these women, the date of pregnancy outcome was the
study entry date. Participants were re-contacted for follow-up in
1976. In both the WHS and the Dieckmann cohorts, DES exposure
(or lack thereof) was documented in the medical record, the
occurrence of cancer was confirmed by medical record, and cause
of death was verified by death certificate.
Follow-up of the combined cohort was implemented by the
National Cancer Institute (NCI) in 1992, at which time intense
tracing efforts were used to locate the women who previously
participated in the WHS and Dieckmann studies. In conjunction
with the 1994 data collection phase, we obtained either a
questionnaire (including proxy questionnaires) or a death
certificate for 6495 (84%) of the 7758 women initially ascertained
for the WHS and Dieckmann studies. Deaths occurring through
the 1994 data collection phase were ascertained by death
certificate; subsequently, mortality and cause of death were
ascertained through the National Death Index. For a subset of
the WHS women (those initially ascertained through the Mayo
Clinic), the underlying cause of death was determined through the
Social Security Death Index. Follow-up through both sources
continued through 1 January 2000.
For the present analysis, the outcomes were all-cause mortality,
cause-specific mortality, including overall cancer death, and cause-
specific cancer death. Diseases were classified by trained
nosologists according to the International Classification of
Diseases (ICD), using both ICD-9 (Hart, 2000) and ICD-10
(WHO, 2003). Outcomes represented by fewer than 10 events
were classified as ‘other’, except when the outcome was potentially
relevant to DES exposure (i.e., vulvar/vaginal and other gynaeco-
logic cancers).
The analyses are based on 7675 of the 7758 women from the
original cohorts (83 women were omitted owing to lack of
information on study entry date). Covariate information was
available for 7062 (92%) women, based predominantly on the 1994
questionnaire responses, or on earlier questionnaire responses
when necessary. Cox proportional hazards models (Cox, 1972),
with time since study entry as the timescale, were used to estimate
mortality rate ratios associated with DES exposure. The women
contributed person-time from the date of study entry until the
date of death, or 1 January 2000, whichever occurred first. For
the outcomes of ovarian, uterine, and cervical cancer, separate
analyses censored follow-up at the date of hysterectomy. In
general, the analyses were conducted in the combined cohorts; in
the presence of interaction between DES and cohort, the outcomes
are reported separately for the WHS and Dieckmann cohorts. To
assess departure from the proportional hazards assumption, we
assessed log–log survival plots and formally tested interaction
terms between DES and time (since study entry) in relation to the
study outcomes.
Year of birth and study entry year were covariates in all models.
Additional covariates, including education (in years; 0–8, 9–12,
13–16, X17), smoking (ever, never), and body mass index (BMI)
(kgm
 2)( p21, 21–23, 24–27, X28) were considered when
available and appropriate for specific mortality outcomes. Breast
cancer models contained terms for family history of breast cancer,
BMI, age at first pregnancy (o20, 20–24, 25–29, 30–39, X40),
and parity (1–2, 3–4, X5); ovarian cancer analyses were adjusted
for parity. We found no evidence of confounding by these
variables or by cohort (RR estimates changed less than 10%);
consequently, the RR shown in the tables are adjusted for birth
year and study entry year. Missing covariate data were included in
models by use of indicator variables.
RESULTS
Table 1 shows the current status of the 7675 women on whom our
analyses are based. Of these, 2237 (29.1%) (1156 exposed, 1081
unexposed) were known to have died and cause of death was
determined for 2193 (98.0%) (1128 exposed, 1065 unexposed).
Exposed and unexposed women in the combined cohort were of
comparable age at study entry. Education, BMI, parity, and
smoking history, when available, were similar for the exposed and
unexposed (Table 2).
In the combined cohort, the RR for DES in relation to all-cause
mortality was 1.06 (95% CI¼0.98–1.16) (Table 3). When breast
cancer deaths were not counted as outcomes, the RR was 1.05 (95%
CI¼0.96–1.14) in the combined cohort, 1.03 (95% CI¼0.94–
1.13) in WHS, and 1.12 (95% CI¼0.91–1.39) in the Dieckmann
cohort. After additional adjustment for BMI and smoking, and
with breast cancer omitted, the RR was 1.11 (95% CI¼1.02–1.21)
in the combined cohort; the findings were identical for the
individual cohorts.
The combined grouping of cerebrocardiovascular disease
accounted for about one-third (33.8%) of all deaths, but there
was little evidence that DES increased overall cerebrocardiovas-
cular mortality or mortality from cardiovascular, cerebrovascular,
or other vascular conditions.
Table 1 Status of the original cohorts
Women’s Health Study Dieckmann Study
Exposed Unexposed Exposed Unexposed Total
Status of cohorts
Initial members
a 3031 3014 826 804 7675
Ever followed 2885 2816 693 668 7062
Deceased 931 900 225 181 2237
Cause of death known 909 887 219 178 2193
1994 Quest returned 2079 2011 425 430 4945
Lost to follow-up
b 112 180 150 181 623
aOf 7758 women in the initial cohort, 83 WHS women were removed owing to an unknown study entry date.
bAt the time of the 1994 follow-up.
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to infectious disease, neuropsychiatric conditions, Alzheimer’s
disease, digestive diseases, and diabetes were compatible with
chance. A moderately strong and statistically significant associa-
tion was observed between DES exposure and deaths owing to
kidney/urinary tract disease (RR¼2.39; 95% CI¼1.14–4.99), and
the RR was 2.57 (95% CI¼1.23–5.39) after further adjustment for
smoking. Mortality from violence/accident was similar for the
exposed and unexposed women. There was little evidence of an
association between DES and noncancer mortality classified as
‘other’; RR¼0.90 (95% CI¼0.62–1.29). Inverse associations were
observed for pulmonary and liver disease mortality in relation to
DES exposure, but were consistent with chance, and the results
were similar after adjustment for smoking (data not shown).
Overall, 37.7% of deaths were owing to cancer (Table 3). In the
combined cohort, the RR for overall cancer mortality was 1.07
(95% CI¼0.94–1.23). In analyses that omitted the breast cancer
outcomes, the RR was 1.02 (95% CI¼0.88–1.19) in the combined
cohort, 0.96 (95% CI¼0.81–1.14) in the WHS, and 1.37 (95%
CI¼0.94–2.00) in the Dieckmann cohort. The interaction between
DES exposure and cohort in relation to overall cancer mortality
was not statistically significant (P¼0.11). After further adjustment
for BMI and smoking, and with breast cancer deaths omitted, the
RR for overall cancer mortality was 1.09 (95% CI¼0.94–1.28) in
the combined cohort, 1.06 (95% CI¼0.90–1.26) in WHS, and 1.35
(95% CI¼0.92–1.97) in the Dieckmann cohort.
In the combined cohort, the RR was 1.27 (95% CI¼0.96–1.69)
for the association between DES and breast cancer death; after
further adjustment for family history of breast cancer, BMI, age at
first pregnancy, and parity, the RR was 1.38 (95% CI¼1.03–1.85).
The RR was 1.12 (95% CI¼0.80–1.55) in the WHS cohort and 1.82
(95%¼1.04–3.18) in the Dieckmann cohort, but the interaction
between DES and cohort in relation to breast cancer mortality was
not statistically significant (P¼0.15). The association with breast
cancer mortality did not change over time; the RR was 1.31 and
1.25, respectively, for less than 30 years, and 30 or more years since
exposure.
Diethylstilbestrol was not associated with an increased risk of
death due to ovarian cancer (RR¼0.87; 95% CI¼0.51–1.46); the
RR was essentially the same after adjustment for parity, and when
follow-up was censored at hysterectomy. The RR were 1.48 (95%
CI¼0.53–4.17) and 0.25 (95% CI¼0.05–1.18), respectively, for
the associations with uterine and cervical cancer mortality, and
both RR were materially unchanged after adjustment for smoking
and when follow-up was censored at hysterectomy. There was no
association with vulvar/vaginal cancer (RR¼1.00; 95% CI¼0.20–
4.93).
The RR suggested elevated risk of death from lung, urinary, and
head and neck cancer, as well as non-Hodgkin’s lymphoma,
melanoma, and leukaemia, but confidence intervals were wide and
included the null value. Further adjustment for smoking did not
materially change the RR of the cancers known to be associated
Table 2 Characteristics of women in the combined cohort, by DES
exposure status
Exposed, Unexposed,
N¼3857, N¼3818,
Factor number (%) number (%)
Age at study entry
o25 1101 (28.6) 1087 (28.5)
25–29 1362 (35.3) 1344 (35.2)
30–34 832 (21.6) 867 (22.7)
X35 562 (14.6) 520 (13.6)
Mean age at study entry 28.1 28.1
Years of education
a
0–8 164 (6.7) 188 (8.0)
9–12 1205 (49.0) 1139 (48.5)
13–16 899 (36.5) 838 (35.7)
X17 193 (7.8) 182 (7.8)
Missing 1396 1471
Mean years of education 13.0 12.9
Body mass index
b
o21 365 (13.1) 357 (13.1)
21–23 1040 (37.3) 935 (34.4)
24–27 892 (32.0) 957 (35.2)
X28 493 (17.7) 469 (17.3)
Missing 1067 1100
Mean body mass index 24.4 24.5
Ever smoked77
No 1700 (49.8) 1665 (51.0)
Yes 1712 (50.2) 1600 (49.0)
Missing 445 553
BMI¼body mass index; WHS¼Women’s Health Study.
aEducation missing for
100% of Dieckmann women and 20% of WHS women.
bBMI missing for 40% of
Dieckmann women and 25% of WHS women. The BMI was based on weight at age
50 for WHS women and on current weight at most recent questionnaire response
for the Dieckmann cohort. 77Smoking missing for o1% of Dieckmann women and
16% of WHS.
Table 3 Mortality rate ratios for the combined cohort, by DES exposure
status
Number of deaths
Cause of death Exposed Unexposed RR (95% CI)
a
All mortality 1156 1081 1.06 (0.98–1.16)
Cerebrocardiovascular 383 373 1.02 (0.88–1.18)
Cardiovascular 273 276 0.98 (0.83–1.16)
Cerebrovascular 80 74 1.08 (0.78–1.47)
Other vascular 30 23 1.29 (0.75–2.23)
Infectious 60 43 1.39 (0.94–2.06)
Neuropsychiatric 54 42 1.29 (0.86–1.92)
Alzheimer’s 8 7 1.17 (0.42–3.22)
Pulmonary 37 46 0.80 (0.52–1.24)
Violence/accident 39 38 1.02 (0.65–1.60)
Digestive 27 20 1.34 (0.75–2.40)
Diabetes 26 20 1.30 (0.72–2.32)
Liver 13 22 0.59 (0.30–1.16)
Kidney/urinary 24 10 2.39 (1.14–4.99)
Other (noncancer) 55 61 0.90 (0.62–1.29)
Cancer mortality 438 406 1.07 (0.94–1.23)
Breast 110 86 1.27 (0.96–1.69)
Lung 96 81 1.19 (0.88–1.60)
Colorectal 42 44 0.95 (0.62–1.45)
Upper GI 9 13 0.69 (0.30–1.61)
Other GI 34 34 1.00 (0.62–1.60)
Ovary 26 30 0.87 (0.51–1.46)
Uterine 9 6 1.48 (0.53–4.17)
Cervix 2 8 0.25 (0.05–1.18)
Vulvar/vaginal 3 3 1.00 (0.20–4.93)
Urinary 15 11 1.36 (0.62–2.96)
Brain 10 12 0.83 (0.36–1.93)
Non-Hodgkin’s lymphoma 25 16 1.56 (0.83–2.92)
Leukaemia 15 9 1.66 (0.73–3.80)
Head and neck 9 5 1.80 (0.60–5.36)
Melanoma 7 5 1.39 (0.44–4.37)
Multiple myeloma 2 11 0.18 (0.04–0.82)
Other cancer 24 32 0.75 (0.44–1.27)
GI¼gastrointestinal.
aAdjusted for birth year and year of study entry.
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cancer, cancer of the upper GI tract, and ‘other’ cancer were also
imprecise. The inverse association with death from multiple
myeloma was statistically significant, RR¼0.18 (95% CI¼0.04–
0.82), and was unchanged after adjustment for smoking. The data
provided no evidence that DES was related to death from colorectal
or other GI cancers.
DISCUSSION
Our results are based on the largest mortality study to date of
women with documented exposure to DES during pregnancy, with
over 2000 deaths, of which 800 were from cancer and nearly 200
from breast cancer.
Our data suggest that DES is associated with a small elevation of
all-cause mortality. The finding may reflect residual confounding
by a lifestyle correlate, although the RR was somewhat greater in
the Dieckmann cohort, which consists of women who were
enrolled in a clinical trial of DES and who received high doses of
DES. There was no increase of cerebrocardiovascular deaths, and
the suggested increased risk of vascular deaths was consistent with
chance. Clinical trial results from the Women’s Health Initiative
(WHI) suggest increased risks of cerebrocardiovascular events,
including stroke and thromboembolic events, in postmenopausal
women using equine oestrogens, but the effects may be limited to
current or recent use (Women’s Health Initiative, 2004). Also, WHI
participants were 50–70 years of age at enrolment, whereas women
in our study were in their childbearing years at the time of DES use
and at lower risk of cerebrocardiovascular outcomes. Current
use of menopausal oestrogen may also increase risk of cognitive
impairment (Shumaker et al, 2004), but our data showed no
association with mortality from psychiatric disease or Alzheimer’s
disease. Although the data indicated a moderately elevated
mortality for kidney/urinary disease and an inverse association
with ‘other’ noncancer mortality, both of which were statistically
significant, we assessed a large number of outcomes, and these
findings may represent false positives. We are unaware of human
evidence linking DES to kidney/urinary disease, although DES-
induced structural and functional changes in the renal tissue of
rats have been reported (Onarglioglu et al, 1998).
The increased risk of breast cancer death observed in the
combined cohort is consistent with the large follow-up study of
DES in relation breast cancer mortality (Calle et al, 1996) and with
our previous findings (Titus-Ernstoff et al, 2001). An early analysis
of the Dieckmann data suggested a moderately strong association
with breast cancer mortality (RR¼2.89; 95% CI¼0.99–8.47)
(Clark and Portier, 1979), and our finding in the combined cohort
was largely owing to the elevated mortality in the Dieckmann
group. The association with breast cancer mortality in the
Dieckmann cohort is noteworthy because, unlike the WHS, DES
exposure was in a clinical trial, and was not owing to a history of
pregnancy complications, indicating an aberrant hormonal milieu
or specialised obstetrics care, which might be correlated with
lifestyle characteristics.
Women participating in the Dieckmann trial received especially
high doses of DES resulting in a cumulative dose of 11–12g over
the course of the pregnancy. Based on studies involving women
treated during obstetrics care (Hadjimichael et al, 1984), doses
given to pregnant women in the WHS were probably much lower
(about 1.1g cumulative). Possibly, the stronger association
between DES and breast cancer mortality observed in the
Dieckmann study reflects the higher doses of DES administered
to women in that cohort and/or the clinical trial design, which
should eliminate confounding. However, a study examining dose
in relation to breast cancer risk found no evidence of dose
response (Hadjimichael et al, 1984), and our previous study of
breast cancer incidence in the combined cohort showed similar
risks for WHS and Dieckmann women (Titus-Ernstoff et al, 2001).
Some studies of breast cancer incidence, including two previous
studies based on the WHS and Dieckmann cohorts, suggested
possible latency effects (Bibbo et al, 1978; Colton et al, 1993), but
others did not (Greenberg et al, 1984; Hadjimichael et al, 1984;
Titus-Ernstoff et al, 2001), including a large study conducted in
Connecticut (Hadjimichael et al, 1984). Consistent with previous
reports (Hadjimichael et al, 1984; Calle et al, 1996), we found no
evidence that breast cancer mortality differed according to time
since exposure.
Although findings in the Dieckmann cohort suggested a small
increased risk of overall cancer mortality, even after removing
breast cancer deaths, the results were consistent with chance, as
were the findings for the combined cohort. We also found little
evidence that DES was associated with specific cancers other than
breast cancer. Previous studies of endometrial cancer and DES
during pregnancy or as hormone therapy have produced conflict-
ing results; one study suggested a decreased risk (Hadjimichael
et al, 1984), whereas others showed an increased risk (Hoover et al,
1976; Autunes et al, 1979). In our data, the modestly elevated
mortality rate ratio for uterine cancer was compatible with chance.
We also found no evidence that DES exposure was associated with
ovarian or cervical cancer. Others have suggested increased risk of
ovarian (Hoover et al, 1977; Hadjimichael et al, 1984) and possibly
cervical cancer (Hadjimichael et al, 1984), but case numbers were
small. We also found no indication that DES use during pregnancy
was associated with vaginal/vulvar cancers, tumours that occur
in women exposed to DES in utero (Herbst et al, 1971). We have
no explanation for the strong inverse association with multiple
myeloma, but we assessed numerous outcomes, and the finding
may be a false positive.
The size of the combined cohort, the large number of outcomes,
and the documented use of DES are strengths of our study.
Diethylstilbestrol doses are known for the Dieckmann women,
most of whom received a high cumulative dose, but are unknown
for the WHS participants, precluding assessment of risk according
to dose. Although we had limited information on potential
confounders, some data were available for major health indicators
such as BMI and smoking, and breast cancer risk factors were
available for most women. The possibility of incomplete mortality
ascertainment is a limitation of all studies relying on NDI searches.
Similar proportions of the exposed or unexposed women in the
initial cohort were lost to follow-up as of the 1994 data collection
phase (6.8% exposed, 9.3% unexposed), and cause of death was
ascertained for 97.6% of the exposed and 98.5% of unexposed
decedents. Although incomplete ascertainment may have attenu-
ated some associations, it seems unlikely that ascertainment would
be associated with DES exposure; so our results should not be
biased away from the null.
In summary, our findings indicate that women given DES
during pregnancy experienced a slight but statistically significant
elevation in all-cause mortality after adjusting for covariates and
omitting breast cancer deaths. Our data did not show an elevated
risk of mortality from cancer overall or from gynaecological
cancers. However, an increased risk of breast cancer mortality was
evident, particularly in the Dieckmann women, who received high
doses of DES during pregnancy.
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